HC SVT 1001

Drug Profile

HC SVT 1001

Alternative Names: Adipose-derived-stem-cells-Salvat; Allogeneic-mesenchymal-stem-cells-Salvat

Latest Information Update: 11 Jul 2016

Price : $50

At a glance

  • Originator SALVAT
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Pseudoarthrosis

Most Recent Events

  • 11 Jul 2016 HC SVT 1001 is still in phase I/II trial for Pseudarthrosis in Spain (EudraCT2013-000930-37) (NCT02483364)
  • 29 Apr 2014 Phase-I/II clinical trials in Pseudoarthrosis in Spain (Intraosseous, Implant) (EudraCT2013-000930-37)
  • 31 May 2010 Preclinical trials in Fracture in Spain (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top